# Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).

> **NCT07020377** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amira Bisher,PhD** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes Mellitus
- Non Alcholic Fatty Liver Disease

## Interventions

- **DRUG:** Dapagliflozin (DAPA)
- **DRUG:** Placebo
- **OTHER:** Negative control

## Key facts

- **NCT ID:** NCT07020377
- **Lead sponsor:** Amira Bisher,PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-15
- **Primary completion:** 2025-12-20
- **Final completion:** 2025-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020377, "Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07020377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*